Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

NCT07163273 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT07163273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07163273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Northwell Health
Phase
Phase 2
Overall status
Recruiting
Start date
June 26, 2025
Completion date
June 20, 2027
Enrollment
41 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma